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Proteasomes degrade the majority of proteins in
mammalian cells, are involved in the regulation of
multiple physiological functions, and are established
targets of anticancer drugs. The proteasome has
three types of active sites. Chymotrypsin-like sites
are the most important for protein breakdown and
have long been considered the only suitable targets
for antineoplastic drugs; however, our recent work
demonstrated that inhibitors of caspase-like sites
sensitize malignant cells to inhibitors of the chymo-
trypsin-like sites. Here, we describe the development
of specific cell-permeable inhibitors and an activity-
based probe of the trypsin-like sites. These com-
pounds selectively sensitize multiple myeloma cells
to inhibitors of the chymotrypsin-like sites, including
antimyeloma agents bortezomib and carfilzomib.
Thus, trypsin-like sites are cotargets for anticancers
drugs. Together with inhibitors of chymotrypsin- and
caspase-like sites developed earlier, we provide the
scientific community with a complete set of tools to
separately modulate proteasome active sites in living
cells.
INTRODUCTION
Proteasomes are proteolytic machines that are responsible for
turnover of the majority of proteins in mammalian cells. The
proteasome inhibitor bortezomib (Velcade) is being used for
treatment of multiple myeloma, and at least five second-genera-
tion proteasome inhibitors, carfilzomib (PR-171) (Demo et al.,
2007; O’Connor et al., 2009), NPI-0052 (Chauhan et al., 2005),
CEP-18770 (Piva et al., 2008), MLN-9708 (Kupperman et al.,
2010), and ONX-0912 (PR-047) (Zhou et al., 2009), are in clinical
testing.608 Chemistry & Biology 18, 608–618, May 27, 2011 ª2011 ElsevierProteasomes have three different types of active sites, chymo-
trypsin-like (b5), trypsin-like (b2), and caspase-like (b1). Cells of
the immune system express g-interferon inducible immunopro-
teasomes, which have slightly different catalytic subunits,
namely the b5i (LMP7), b2i (MECL1), and b1i (LMP2). Of these,
the chymotrypsin-like sites (b5 and b5i) have long been consid-
ered as the only suitable targets for drug development. Bortezo-
mib and all drugs presently undergoing trials were developed
to target these sites (Adams, 2004). However, bortezomib,
CEP-18770, and MLN-9708 cotarget the caspase-like sites
(Altun et al., 2005; Berkers et al., 2005; Kisselev et al., 2006; Kup-
perman et al., 2010; Piva et al., 2008), whereas NPI-0052 cotar-
gets trypsin-like and caspase-like sites (Chauhan et al., 2005).
This raises the question of whether inhibition of these sites is
important for these drugs’ antineoplastic activity. Recently, we
have demonstrated that, in most multiple myeloma cell lines,
cytotoxicity of inhibitors does not correlate with inhibition of
the chymotrypsin-like sites but does correlate with loss of spec-
ificity and onset of inhibition of the trypsin-like sites (Britton et al.,
2009). These data strongly suggest that the trypsin-like sites are
important cotargets for antineoplastic agents (Britton et al.,
2009). Cell-permeable inhibitors of these sites are needed to
test this hypothesis.
Efforts to develop specific inhibitors of the trypsin-like site
have met with limited success to date. Most proteasome inhibi-
tors are short N-terminally capped peptides with an electrophilic
group at the C terminus. This electrophile interacts, reversibly or
irreversibly, with the catalytic N-terminal threonine of the protea-
some active site. The peptide moiety of the inhibitor binds to the
substrate binding pocket of the active site and is largely respon-
sible for the specificity (Groll and Huber, 2004; Kisselev and
Goldberg, 2001), although the specificity may be influenced by
the electrophile (Screen et al., 2010). The trypsin-like sites cleave
peptide bonds after a basic residue and also prefer basic resi-
dues in the P3 position (Groll et al., 2002; Harris et al., 2001; Nazif
and Bogyo, 2001). Thus, an ideal inhibitor would have basic resi-
dues, preferably arginines, in the P1 and P3 positions. This pres-
ents a challenge from the synthetic point of view and would,
most likely, render the inhibitor cell-impermeable. In fact, theLtd All rights reserved
Figure 1. Effect of Inhibitors on Purified 26 Protea-
somes
(A) Structures of inhibitors.
(B–D) Inhibition of proteasomes. After 30min incubation of
purified 26S proteasomes with inhibitors, all three activi-
ties were measured with fluorogenic substrates. Mock-
treated proteasomes served as controls. Results are
averages ± SEM of two (B and C) or four (D) independent
experiments. Squares, chymotrypsin-like activity; trian-
gles, caspase-like activity; circles, trypsin-like activity.
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Inhibitors of Proteasome Trypsin-like Sitesfew b2-specific aldehydes (Loidl et al., 1999) and vinyl sulfones
(Groll et al., 2002; Nazif and Bogyo, 2001) are not cell permeable.
A cell-permeable peptide vinyl ester (ve) Hmb-VSL-ve, recently
reported as specific inhibitor of the trypsin-like sites (Marastoni
et al., 2005), did not show any inhibitory activity in our assays
(Screen et al., 2010). Thus, at the onset of our work, no cell-
permeable, b2-specific inhibitors or activity-based probes
were available.
In this work, we describe the development of several cell-
permeable peptide epoxyketone inhibitors as well as an active-
site probe specific to the trypsin-like proteasome sites. We
demonstrate that the most potent of these compounds sensi-
tizes multiple myeloma cells to the specific inhibitors of the
chymotrypsin-like sites, to bortezomib, and to the second-
generation proteasome inhibitor carfilzomib.
RESULTS
Design and Initial Characterization of Inhibitors
We have designed several peptide epoxyketones to target the
trypsin-like site (Figure 1A). Peptide epoxyketones are the
most specific of the several structural classes of proteasomeChemistry & Biology 18, 608–618, May 27inhibitors (Groll and Huber, 2004; Kisselev,
2008; Kisselev and Goldberg, 2001). By forming
a stable morpholino adduct with the protea-
some catalytic N-terminal threonine, they take
specific advantage of the proteasome’s unique
mechanism for cleaving peptide bonds (Groll
et al., 2000). In fact, in more than a decade of
research since the discovery of this class of
proteasome inhibitors (Meng et al., 1999), no
off-target effects of epoxyketones have been
found.
Consistent with the nomenclature used in our
previous work (Britton et al., 2009) we refer to
inhibitors of the trypsin-like sites as NC-0X2,
where ‘‘NC’’ stands for the Norris Cotton
Cancer Center, ‘‘2’’ indicates that a compound
inhibits b2 and b2i sites, and the character in
the position marked by ‘‘X’’ changes from
compound to compound. The first compound,
NC-002 (Ac-LLR-ek), is the epoxyketone
derivative of leupeptin. Leupeptin (Ac-Leu-
Leu-Arg-al) is a cell-permeable inhibitor of
cysteine proteases. In the context of purified
proteasome, this peptide aldehyde is a specific
inhibitor of the trypsin-like sites (Kisselev et al.,2006; McCormack et al., 1998). Peptide aldehydes inhibit serine,
cysteine, and threonine proteases. We reasoned that replacing
the aldehyde in leupeptin with a highly proteasome-specific ep-
oxyketone (Groll et al., 2000) to generate Ac-LLR-amc (NC-002)
would eliminate reactivity with lysosomal cysteine proteases,
retain specificity to the trypsin-like sites, and not alter cell perme-
ability of the compound.
The design of the second compound, NC-012 (Ac-RLR-ek), is
based on the sequence of the best substrate of the trypsin-like
site (Ac-RLR-amc) we developed earlier (Kisselev and Goldberg,
2005). The third inhibitor, NC-022 (Hmb-VSR-ek) has the same
left-handed peptide fragment as the peptide vinyl-ester inhibitor
of the trypsin-like sites reported in the literature (Marastoni et al.,
2005) that lacked inhibitory activity in our hands (Screen et al.,
2010). We chose this fragment because it was optimized to
improve specificity toward these sites.
In order to enable the synthesis of the epoxyketone derivatives
of arginine, we have modified the established procedure for
the synthesis of leucine epoxyketones (Zhou et al., 2009) to allow
for proper protection of the guanidine functional group during
the procedure (see Supplemental Experimental Procedures
available online)., 2011 ª2011 Elsevier Ltd All rights reserved 609
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Figure 2. Effect of Compounds on Proteasomes in
NCI-H929 Cells
(A–C) After overnight treatment with different concentra-
tion of inhibitors, proteasome activities were measured
with Proteasome Glo Assay. Squares, chymotrypsin-like
activity; triangles, caspase-like activity; circles, trypsin-
like activity. Values are averages ± SEMof two (A andC) or
three (B) independent experiments.
(D) Kinetics of inactivation of trypsin-like sites by NC-022.
Concentrations of NC-022 are indicated on the graph.
Similar inactivation rate was observed with NC-002 (Fig-
ure S1). Values are averages ± SEM of two independent
experiments.
(E) NCI-H929 cells were treated with 9 mM NC-002 or
20 mM E-64d (cell-permeable analog of broad specificity
cysteine protease inhibitor E-64) for 6 hr, and cumulative
activity of cathepsins B, L, H, and S was measured in
organellar extracts (Screen et al., 2010).
(F) Extracts of RPMI-8226 cells (which express more im-
munoproteasomes than NCI-H929 cells) were incubated
with inhibitors for 30min at concentrations indicated, then
with 10 mM fluorescent broad spectrum active site probe
MV-151 (Verdoes et al., 2006), followed by fractionation
on SDS-PAGE. Gels were scanned on the Typhoon
Imager (excitation laser-532 nm; emission filter-560 nm).
All three inhibitors block modification of b2 and b2i
subunits by MV-151 to a similar extent, indicating similar
inhibition of both subunits.
(G) Structure of LU-005. Inhibition of proteasome after 1 hr
treatment with LU-005 is presented in Figure S2.
(H) NCI-H929 cells were treated with different concen-
tration of LU-005 for 1 hr followed by continuous treat-
ment with concentrations of NC-022 indicated in the
graph. 48 hr after the start of the treatment, viability was
measured with the Alamar Blue mitochondrial dye con-
version assay. Viability is expressed relative to the control
(mock-treated cells). Values are averages ± SEM of two to
four independent experiments.
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Inhibitors of Proteasome Trypsin-like SitesWe initially evaluated the proteasome inhibitory potential of
our compounds on purified 26S proteasomes from rabbit
muscles (Figures 1B–1D). All three are potent and specific inhib-
itors of the trypsin-like sites. NC-012, as expected for the
compound derived from the best substrate, was the most potent
and specific in the series.
Next we treated NCI-H929 multiple myeloma (MM) cells with
these compounds overnight and determined their proteasome
inhibition profile (Figures 2A–2C). NC-002 and NC-022 specifi-
cally inhibited trypsin-like activity at submicromolar concentra-
tions, but much higher concentrations of NC-012, the most
potent inhibitor of the purified enzyme, were required to achieve
inhibition in live cells. We attribute this decrease in potency with
live cells to poor cell permeability. For cell-permeable com-
pounds, maximal inhibitory effect was achieved within 6–10 hr
after addition of NC-022 (Figure 2D) or NC-002 (Figure S1).
Importantly, NC-002, the epoxyketone derivative of the cysteine
protease inhibitor leupeptin, does not inhibit lysosomal cysteine
proteases (Figure 2E).610 Chemistry & Biology 18, 608–618, May 27, 2011 ª2011 Elsevier Ltd All rights reseMultiple myeloma cells express constitutive
proteasomes and immunoproteasomes, and
substrates used for the measurement of activity
(Figures 2A–2C) are cleaved by both. To deter-mine whether there are any differences in inhibition of constitu-
tive proteasomes or immunoproteasomes by NC-002, NC-012,
and NC-022 we used the fluorescent activity-based probe
MV-151 (Verdoes et al., 2006) in a label-competition experiment.
Extracts of RPMI-8226 MM cells (which express more immuno-
proteasomes than NCI-H929 cells) were treated first with the NC
inhibitors and then with the MV-151 probe. This was followed by
fractionation on SDS-PAGE to separate proteasome subunits
and by imaging to reveal those subunits labeled by the probe
(i.e., unmodified by the inhibitors). All three inhibitors blocked
modification of b2 and b2i sites by the probe to a similar extent
(Figure 2F). Thus, we conclude that NC-002, NC-012, and
NC-022 are equipotent inhibitors of the trypsin-like sites of
constitutive and immunoproteasomes.
Specific Inhibitors of Trypsin-like Sites Sensitize Cells
to Specific Inhibitors of Chymotrypsin-like Sites
Next, we used our compounds to characterize trypsin-likes
sites as targets and cotargets of antineoplastic agents. For thisrved
Figure 3. Az-NC-002 Is a b2/b2i-Specific Active
Site Probe
(A) Structure of the probe and biotinylated phosphane
(BioP).
(B–E) NCI-H929 cells were treated overnight with 9 mM
az-NC-002 or mock-treated (control): subsequently,
activity of three sites was measured (B), whole cell
extracts were prepared, treated with biotinylated phos-
phane BioP (100 mM) for 1 hr, and divided into two uneven
portions. After additional 1 hr treatment with 2 mM
biotinylated irreversible inhibitor AdaBio (AdaK(Bio)
Ahx3L3VS) to mark the migration of all active subunits on
the gel (Kessler et al., 2001), a smaller portion of the
samples was analyzed by gel electrophoresis and
western blot. The membrane was probed with IRDye800-
labeled streptavidin (C). A larger portion was used for the
isolation of biotinylated polypeptides on Streptavidin
beads. Isolated proteins were identified by mass-spec-
trometry (D). Only proteins reproducibly pulled down from
az-NC-002-treated but not from control extracts and
identified by at least two high probability peptides in each
of the two replicate experiments are presented in the
table. Additional data from mass-spectrometric experi-
ment are provided in Table S1. (E) Analysis of the isolation
by western blot. Load, sample loaded on Streptavidin-
magnetic bead column; FT, unbound fraction; eluate,
biotin eluate. Percentages of the total loaded on the gel
are indicated in parenthesis.
(F and G) Effect of az-NC-002 and NC-022 on cathepsin D
activity in NCI-H929 cells. Cells were treated with inhibi-
tors for 6 hr at concentrations indicated and cathepsin D
activity was measured (F). Cells were treated with 27 mM
inhibitors for 24 hr and combined activity of cathepsin D
and E was measured (G). Mock-treated cells served as
control.
Values in (B), (G), and (H) are averages ± SEM of two to
three independent experiments.
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Inhibitors of Proteasome Trypsin-like Sitespurpose we used NC-022, the most potent cell-permeable
inhibitor. First we tested whether selective inhibition of trypsin-
like sites is sufficient to reduce cell viability. We treated
NCI-H929 cells with NC-022 for 48 hr and assayed cell viability
with Alamar Blue mitochondrial conversion dye. No loss of
viability was detected even at concentrations that completely
inhibited the trypsin-like sites (data not shown). Thus, targeting
trypsin-like sites is not sufficient to induce cytotoxicity in
multiple-myeloma cells. (It should be noted that NCI-H929 is
the most sensitive to proteasome inhibitors among myeloma
cell lines [Britton et al., 2009]).
We next tested whether NC-022 sensitizes myeloma cells to
inhibitors of the chymotrypsin-like sites. In the past few years,
we have developed several peptide epoxyketone inhibitors of
the chymotrypsin-like sites (Britton et al., 2009; Geurink et al.,
2010); in these experiments we used the most specific of these,
a pentafluorophenylalanine-containing compound referred to as
here as LU-005 (Figure 2G; Figure S2) (Geurink et al., 2010) (‘‘LU’’
stands for Leiden University and ‘‘5’’ indicates that the
compound targets b5/b5i active sites). In the first experiment,Chemistry & Biology 18, 608–618, May 27we determined whether NC-022 sensitizes cells
to LU-005, andwhat concentrations are needed
to achieve this sensitization. Consistent with the
treatment condition used in our previous work(Britton et al., 2009), where we demonstrated that a specific
inhibitor of the caspase-like sites sensitizes myeloma cells to
NC-005 (a specific inhibitor of chymotrypsin-like sites), we
treated cells with LU-005 for 1 hr and then incubated them in
the presence of different concentrations of NC-022 for 48 hr,
whereupon an Alamar Blue assay for cell viability was performed.
Dramatic dose-dependent sensitization was observed, with the
IC50 of LU-005 increasing up to 8.5-fold. This maximal sensitiza-
tion was achieved at 3 mM NC-022 (Figure 2H), which causes
90% inhibition of the trypsin-like sites within 4–6 hr after addition
of NC-022 (Figure 2D). NC-002 caused similar sensitization to
NC-005 (data not shown). Thus, near-complete inhibition of the
trypsin-like sites is needed to achieve maximal sensitization
effect.
Development of a b2-Specific Activity-Based Probe
To further confirm that our compounds are specific for the
trypsin-like sites and that their biological activity is not due to
off-target effects, we have synthesized az-NC-002, an NC-
002-derived, activity-based probe (Figure 3A). We have chosen, 2011 ª2011 Elsevier Ltd All rights reserved 611
Chemistry & Biology
Inhibitors of Proteasome Trypsin-like SitesNC-002 over NC-022 for derivatization because it was easier to
introduce an azido group into this molecule. Addition of the azido
group does not alter the specificity of the inhibitor (Figure 3B).
Polypeptides modified by this probe were visualized on western
blot after treating extracts of probe-treated NCI-H929 cells with
azido-reactive biotinylated phosphane (BioP) in a Staudinger-
Bertozzi ligation (Ovaa et al., 2003). One major az-NC-002-
specific streptavidin-reactive band was detected (Figure 3C,
lane 5). This matches the size of the band of the b2 subunit,
which harbors the catalytic threonines of the trypsin-like sites.
A weaker band of slightly lower mobility, matching the mobility
of b2i band, was also detected. Corroborating that these bands
are of proteasomal subunits, az-NC-002 treatment prevented
subsequent modification of b2 and b2i subunits by another
proteasome-specific probe (Ada-K[Bio]-Ahx3L3VS, lane 4).
(A number of endogenously biotinylated proteins in the 70–
100 kDa region were also detected and can serve as a loading
control.)
To further confirm that the probe covalently modifies b2 and
b2i subunits, we denatured the proteasome after BioP modifica-
tion, isolated biotinylated polypeptides on streptavidin beads,
and identified bound polypeptides by mass spectrometry after
on-beads trypsin digestion. Peptides derived from b2 and b2i
subunits were present in the samples isolated from extracts of
the probe-treated cells but not from extracts of the control cells
(Figure 3D; Table S1). No peptides derived from other catalytic
subunits were detected. Thus, we conclude that az-NC-002 is
a trypsin-like site-specific activity-based probe.
Surprisingly, several other polypeptides were also reproduc-
ibly identified as specific az-NC-002 targets. These include the
aspartic protease cathepsin D (29 kDa), molecular chaperone
hsc71 (71 kDa), and thioredoxin domain-containing protein
TXNDC5 (48 kDa, Figure 3D). Of these, lysosomal aspartic
protease cathepsinD (Beneset al., 2008)wasof greatest concern
to us. It has the samemolecularweight as theb2subunit, so some
of the streptavidin-reactive material in the b2-band (Figure 3C)
may be cathepsin D. To determine the significance of this poten-
tial off-target effect, we measured inhibition of cathepsin D by
az-NC-002 but could not detect any significant inhibition (Figures
3F and 3G). We conclude that this probe either reacts with
cathepsin D outside of the active site or inhibits a small fraction
of the enzyme, detectable in the mass spectrometry experiment
but not in the activity assay. Similarly, NC-022 did not inhibit
cathepsin D even at concentrations as high as 27 mM (Figure 3G).
Thus, chemical modification of cathepsin D is unlikely to
contribute to the biological effects of the NC compounds.
There are no major streptavidin-reactive az-NC-002-specific
bands in the 45–50 kDa and 70 kDa region of the gel, where
two other targets of az-NC-002, TXNDC5 and hsc71, migrate
(Figure 3C). Probe modification of these proteins is responsible
for one of the background bands in lane 5 on Figure 3C. We
used western blot to determine which fraction of cellular hsc71
binds to streptavidin beads in extracts of az-NC-002-treated
cells. Under conditions whenmost of b2-antibody reactivemate-
rial was detected in streptavidin-bound fraction, the majority of
hsc71-antibody reactive material was detected in the streptavi-
din-unbound fractions (Figure 3E). Thus, az-NC-022 modifies
a small fraction of hsc71 and is therefore very unlikely to affect
the overall protein-folding capacity of the cell.612 Chemistry & Biology 18, 608–618, May 27, 2011 ª2011 ElsevierTrypsin-like Sites Are Better Cotargets of Antimyeloma
Agents than Caspase-like Sites
In the next set of experiments (Figure 4), we tested whether
NC-022 sensitizes other MM cells to LU-005 and whether it is
a more potent sensitizer than a specific inhibitor of caspase-
like sites NC-001 (Britton et al., 2009). We have chosen four
additional myeloma cell lines, MM1.R, RPMI-8226, KMS-18,
and KMS-12-BM, for these experiments. These cell lines vary
up to 40-fold in their sensitivity to bortezomib and NC-005 (Brit-
ton et al., 2009). In all experiments, NC-022 was used at
a concentration that inhibited trypsin-like activity by more than
90% after 6 hr incubation.
In all MM cell lines, NC-022 reduced the IC50 for LU-005 by
4- to 10-fold. In three (MM1.R, RPMI-8226, KMS-18), NC-022
caused similar sensitization as NC-001 (Figures 4C–4E). In two
others (NCI-H929 and KMS-12-BM, Figures 4A and 4B),
NC-022 was a more potent sensitizer than NC-001. Thus, the
trypsin-like sites are important cotargets of antineoplastic drugs
in multiple myeloma cells; in fact, they are better cotargets than
the caspase-like sites.
To confirm that LU-005 functions as a specific inhibitor of the
chymotrypsin-like sites and to determine whether sensitization
occurs upon clinically achievable inhibition of the chymo-
trypsin-like sites, we measured inhibition of all sites at the end
of 1 hr treatment with LU-005 (Table 1). In patients treated with
bortezomib, inhibition of the chymotrypsin-like sites that can
be achieved at maximal tolerated doses does not exceed 70%
(Hamilton et al., 2005); in patients treated with carfilzomib, it
approaches 90% (O’Connor et al., 2009). As can be seen from
Table 1, in all but the KMS-18 cell line, sensitization by NC-022
is observed upon clinically achievable 50%–80% inhibition of
the chymotrypsin-like sites. Thus, sensitization of myeloma cells
to specific inhibitors of the chymotrypsin-like sites by NC-022 is
of potential clinical significance.
Effects of Combined Inhibition of Caspase-like
and Trypsin-like Sites on Myeloma Cells
Due to the lack of effective, selective, and cell-permeable inhibi-
tors of the trypsin-like sites, the effects of combined inhibition
of the trypsin-like and caspase-like sites (in the absence of inhibi-
tion of the chymotrypsin-like sites) on growth and viability of
mammalian cells could not be studied hitherto. We observed
that continuous exposure to a mixture of NC-022 and NC-001
(at concentrations at which caspase-like and trypsin-like sites
are both blocked by more than 90%) reduced cell viability by
20%–50% (Figure 4F). Proteasome inhibitors block cell prolifera-
tion and induce apoptosis. This moderate decrease could be
aconsequence of inhibition of cell proliferationwithout cell death.
To determine whether apoptosis occurs, we measured caspase
activation in the NCI-H929 and MM1.R cell lines. We found that
treatment with a combination of NC-001 and NC-002, in contrast
to LU-005 treatment, did not cause any significant increase in
caspase activity (Figure 4G). Therefore, we conclude that the
moderate decrease in viability in cells cotreated with NC-001
and NC-002 is not due to apoptosis and most likely reflects inhi-
bition of cell proliferation. We would like to emphasize that this is
the first example of a biological effect on mammalian cells due to
inhibition of the caspase-like and trypsin-like sites in the absence
of inhibition of the chymotrypsin-like sites.Ltd All rights reserved
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Figure 4. Comparative Analysis of Sensitization of Different Myeloma Cells to Specific Inhibitor of the Chymotrypsin-like Sites (LU-005) by
NC-022 and Specific Inhibitor of Caspase-like Sites (NC-001)
(A–E) Sensitization of various MM cells to LU-005. Multiple cells were treated with LU-005 for 1 hr and then divided into five aliquots. Four aliquots were cultured
further in the presence of either NC-022 (circles), or 2 mM NC-001 (triangles), or both (diamonds), or in the absence of inhibitors (squares). Concentration of
NC-022 (27 mM in RPMI-8226, 9 mM in KMS-12-BM, 3 mM in all other cell lines) was adjusted to inhibit the trypsin-like activity by 90% within first 3–6 hr of
incubation. The fifth aliquot was used to measure proteasome inhibition, which is presented in Table 1.
(F) After 48 hr treatment with 2 mM NC-001 and/or NC-022 (same concentrations as in A and B), cell viability was measured with Alamar Blue.
(G) Effect of NC-001 and NC-022 on apoptosis in NCI-H929 andMM1.R cells. After 9 hr incubation with inhibitors, caspase-3/7 activity was measured. Values on
all graphs are averages ± SE of two to three independent experiments.
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Inhibitors of Proteasome Trypsin-like SitesWe next studied the effects of the mixture of NC-001 and
NC-022 on MM cells sensitivity to LU-005. As in the previous
experiments, cell were treated with LU-005 for 1 hr and then
cultured with a NC-001/NC-022 mixture after removal ofChemistry & Biology 18,LU-005. The mixture of NC-001 and NC-022 appeared to be
a much stronger sensitizer than NC-022 alone (Figures 4A–4E).
Notably, there was always a concentration of LU-005 at which
a mixture of NC-001 and NC-002 caused a dramatic loss of608–618, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 613
Table 1. NC-022 and, More Dramatically, a Mixture of NC-022 and NC-001 Sensitize Multiple Myeloma Cells to LU-005 upon Clinically
Achievable Proteasome Inhibition
Viability (% Control) Inhibition of Active Sites (% Control)
Cell line LU-005 (mM) -NC-022 +NC-022 +NC-002 & NC-001 b5 b2 b1
NCI-H929 0.11 30 ± 2 2 ± 1 0.65 ± 0.25 86 ± 3 11 ± 4 6 ± 8
0.043 80 ± 8 10 ± 2 1.5 ± 0.5 72 ± 8 6 ± 4 15 ± 20
0.011 94 ± 11 48 ± 3 10 ± 4 48 ± 5 6 ± 1 5.5 ± 4.5
0.004 100 ± 13 69 ± 0 36 ± 14 22 ± 11 13 ± 7 7 ± 10
0.0014 97 ± 9 77 ± 2 50 ± 17 22 ± 4 9 ± 2 14 ± 15
MM1.R 0.11 47 ± 42 1.7 ± 0.2 1.2 ± 1.2 76 ± 3 23 ± 4 27 ± 5
0.043 88 ± 20 18.5 ± 5.5 2.8 ± 1.5 54 ± 12 5 ± 11 6 ± 12
0.011 106 ± 4 57 ± 10 15 ± 9 31 ± 10 5 ± 1 3 = 16
0.004 102 ± 4 66 ± 1 26 ± 6 17 ± 4 6.5 ± 0.5 6 ± 8
RPMI-8226 1.0 10 ± 10 6 ± 3 1 ± 0 82 ± 16 22 ± 19 37 ± 4
0.33 94 ± 1 31 ± 9 4.6 ± 0.7 62 ± 32 13 ± 11 37 ± 15
0.11 108 ± 4 95 ± 2 39 ± 5 49 ± 30 3 ± 5 23 ± 2
0.037 109 ± 2 104 ± 5 76 ± 3 45 ± 26 1 ± 17 16 ± 7
0.012 109 ± 1 108 ± 4 82 ± 11 16 ± 8 21 ± 4 34 ± 5
KMS-12-BM 1.0 27 ± 6 1.5 ± 0.1 1 ± 0 95 ± 2 29 ± 7 11 ± 16
0.33 80 ± 9 12 ± 2 2 ± 0 81 ± 3 3 ± 18 6 ± 12
0.11 94 ± 16 65 ± 2 20 ± 4 56 ± 9 4.7 ± 1.1 3 ± 16
0.037 89 ± 8 90 ± 5 50 ± 2 48 ± 9 12 ± 1 1 ± 5
0.012 101 ± 5 104 ± 9 79 ± 6 16 ± 8 21 ± 3.5 34 ± 5
KMS-18 9.0 45 ± 8 17.5 ± 7.5 0.8 ± 0.2 97 ± 1 62 ± 5 42 ± 2
3.0 72 ± 2 24 ± 8 1 ± 0.1 94 ± 4 50 ± 14 39 ± 12
1.0 88 ± 16 29 ± 12 8 ± 4 85 ± 6 38 ± 5 32 ± 4
0.33 108 ± 0 106 ± 16 33 ± 20 69 ± 8 24 ± 6 29 ± 7
0.11 108 ± 1 106 ± 4 56 ± 16 47 ± 4 12 ± 16 21 ± 16
0.037 108 ± 1 104 ± 3 79 ± 14 14 13 ± 13 0 ± 8
Results of proteasome inhibition and viability measurements form experiment shown in Figure 4. Cells were treated with LU-005 for 1 hr, followed by
measurement of peptidase activities; a fraction of the cells was cultured in the presence of NC-022, of NC-022 and NC-001, or of none of the inhibitors
for 48 hr, whereupon cell viability wasmeasured. Viability values are the same as in the graphs in Figure 4. Values are averages ± SEMof two (activity) or
three (viability) independent measurements. Negative values indicate activation. See caption of Figure 4 for further experimental details.
Chemistry & Biology
Inhibitors of Proteasome Trypsin-like Sitescell viability as compared to the effect of LU-005 as a single
agent (i.e., from 80%–100% to 10%–20%, Figures 4A–E). At
this concentration, LU-005 inhibited chymotrypsin-like sites by
a clinically achievable 50–85% (Table 1). A mixture also sensi-
tized cells at much lower concentrations of LU-005 (i.e., upon
much smaller inhibition of chymotrypsin-like sites, Table 1)
than either NC-001 or NC-002 alone.
NC-022 Specifically Sensitizes Myeloma Cells
to Bortezomib and Carfilzomib
To further strengthen the clinical relevance of our observations,
we tested whether NC-022 sensitizes MM cells to the FDA-
approved proteasome inhibitor bortezomib and to carfilzomib,
a second-generation peptide epoxyketone proteasome inhibitor
undergoing phase II–III clinical trials (Demo et al., 2007; O’Con-
nor et al., 2009). We used two cell lines in these experiments,
one of the most bortezomib-sensitive (NCI-H929) and one of
the most bortezomib-resistant (KMS-12-BM) (Britton et al.,
2009). Both cell lines were sensitized to the two agents (Figure 5).
In NCI-H929 cells, sensitization to both compounds occurred
upon clinically achievable proteasome inhibition (Table 2). In614 Chemistry & Biology 18, 608–618, May 27, 2011 ª2011 ElsevierKMS-12-BM cells, sensitization to bortezomib, although more
dramatic than in NC-H929 cells, was observed above clinically
achievable inhibition of the chymotrypsin-like sites. Sensitization
to carfilzomib was observed at clinically achievable levels.
To assess whether coinhibition of trypsin-like sites increases
toxicity to normal cells, we tested whether NC-022 increases
toxicity of bortezomib and carfilzomib to peripheral bloodmono-
nuclear cells (PBMNCs). NC-022 did not sensitize cells from any
of the three donors to either of two agents (Figure 5; Figure S3).
This lack of sensitization is surprising because NC-001 sensi-
tizes PBMNCs to inhibitors of the chymotrypsin-likes sites (Brit-
ton et al., 2009). Thus, NC-022 selectively sensitizes malignant
MM cells to bortezomib and carfilzomib.
DISCUSSION
Site-specific, cell-permeable inhibitors of the proteasome’s
trypsin-like sites have long been missing from the otherwise
impressive palette of reagents available to study the role of the
proteasome and its active sites in different aspects of cellular
function. The compounds described herein fill this void.Ltd All rights reserved
NCI-H929
0
50
100
1 10 100 1000
bortezomib (nM)
no NC-022
NC-022
NCI-H929
0
50
100
1 10 100 1000
carfilzomib (nM)
no NC-022
NC-022
KMS-12-BM
0
50
100
10 100 1000
carfilzomib (nM)
no NC-022
NC-022 only
KMS-12-BM
0
50
100
10 100 1000
bortezomib (nM)
no NC-022
NC-022
PBMNC, donor 1
0%
50%
100%
150%
1 10 100 1000
carfilzomib (nM)
no NC-022
NC-022
PBMNC, donor 1
0%
50%
100%
150%
1 10 100 1000
bortezomib (uM)
no NC-022
+ NC-022
Figure 5. NC-022 Specifically Sensitizes Multiple Myeloma Cells to Bortezomib and Carfilzomib
NCI-H929, KMS-12-BM, or PBMNC cells were treated with bortezomib or carfilzomib for 1 hr and then with NC-022 for 48 hr after which their viability was
measured. NC-022 (3 mM in NCI-H929 and 9 mM in KMS-12-BM) was used at concentrations that inhibit trypsin-like activity by more than 90%. Proteasome
activity was measured immediately after 1 hr bortezomib and carfilzomib treatment and 5 hr after the start of NC-022 treatment, and is presented in Table 2.
Results of treatments of PBMNC from two additional donors are presented in Figure S3. Results are means ± SEM of two to three independent experiments.
Squares, post-bortezomib/carfilzomib culturing in the absence of NC-022; circles, culturing in the presence of NC-022.
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Inhibitors of Proteasome Trypsin-like SitesThe significance of this work is two-fold. First, it describes the
development of (1) cell-permeable specific inhibitors of the
trypsin-like sites of the proteasome and (2) an active site probe
derived from these inhibitors. Second, we use one of these
compounds, NC-022, to demonstrate that these sites are cotar-
gets of antineoplastic drugs in multiple myeloma. Trypsin-like
sites appear to be better cotargets than caspase-like sites for
two reasons. First, in two out of five cell lines tested, NC-002
caused better sensitization to chymotrypsin site-specific inhib-
itor than NC-001, while in three others sensitization was similar
(Figure 4). Second, NC-022 selectively sensitized MM cells to
carfilzomib and bortezomib (Figure 5); sensitization by NC-001
was not selective (Britton et al., 2009). It remains to be deter-
mined whether NC-022 could be developed into a drug to be
used in combination with bortezomib and carfilzomib or whether
development of newer agents that inhibit chymotrypsin- and
trypsin-like sites with equal potency would be a better approachChemistry & Biology 18,to translate the results of this work into novel treatments for
patients.
The importance of this work goes beyond oncology. Several
years ago, we found that the ability of leupeptin (used as specific
inhibitor of the trypsin-like sites of purified proteasomes) to block
degradation of model substrates depends on the content of
basic residues in a substrate (Kisselev et al., 2006). Using inhib-
itors developed in this work as well as proteomic approaches,
we can now ask whether basic proteins will be selectively stabi-
lized upon treatment of cells with b2-specific proteasome
inhibitors.
Proteasomes are involved in a variety of biological processes
(e.g., inflammation and immune response). One immediate
application of these compounds would be to study the role of
trypsin-like sites in the generation of MHC class I epitopes.
Although it is well established that these peptides or their precur-
sors are generated by proteasomes, the role of individual active608–618, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 615
Table 2. NC-022 Sensitizes Multiple Myeloma Cells to Bortezomib and Carfilzomib upon Clinically Achievable Proteasome Inhibition
Inhibition of Active Sites (% control)
Chymotrypsin-like Sites Trypsin-like Sites
Time after Start of Experiment Time after Start of Experiment
Inhibitor Viability (% Control) 1 hra 6 hr 6 hr 1 hr 6 hr 6 hr
Cell Line (nM) - NC-022 +NC-022 -NC-022 +NC-022 -NC-022 +NC-022
NCI-H929 Bortezomib
100 2.9 ± 1.5 1.9 ± 1.5 96 ± 2 86 ± 1 93 ± 2 36 ± 17 45 ± 2 96 ± 1
33 53 ± 17 19 ± 19 89 ± 2 85 ± 4 48 ± 35 26 ± 15 31 ± 0 94 ± 1
11 106 ± 2 65 ± 1 64 ± 7 41 ± 3.5 34 ± 29 8 ± 11 14 ± 2 93 ± 2
3.7 107 ± 5 85 ± 3 9 ± 7 13 ± 1 14 ± 13 0 ± 7 6 ± 4 93 ± 2
KMS-12-BM 900 14 ± 12 3.8 ± 2.5 93 ± 5 84 ± 16 88 ± 5 28 ± 5 26 ± 19 93 ± 1
300 66 ± 9 14 ± 11 93 ± 3 76 ± 18 83 ± 6 22 ± 12 24 ± 18 91 ± 2
100 92 ± 9 42 ± 10 90 ± 6 64 ± 23 75 ± 6 19 ± 3 15 ± 11 92 ± 1
33.3 98 ± 13 72 ± 1 82 ± 8 56 ± 24 62 ± 7 10 ± 11 8 ± 15 92 ± 0
NCI-H929 Carfilzomib
33 30 ± 11 4 ± 2 75 ± 17 95 ± 7 71 ± 23 17 ± 8 46 ± 24 94 ± 3
11 78 ± 15 14 ± 8 39 ± 35 89 ± 11 52 ± 32 0 ± 14 39 ± 36 93 ± 2
3.7 99 ± 9 36 ± 15 14 ± 43 65.5 41 ± 29 7 ± 18 3 93 ± 3
KMS-12-BM 900 41 ± 7 9 ± 1 98 ± 3 97 ± 0 99 ± 4 75 ± 14 72 ± 2 94 ± 3
300 71 ± 2 15 ± 1 97 ± 3 97 ± 1 95 ± 4 49 ± 18 69 ± 2 93 ± 2
100 83.5 ± 3 27 ± 5 95 ± 3 97 ± 1 90 ± 3 18 ± 8 62 ± 2 94 ± 2
33 91 ± 3 40 ± 3 90 ± 3 97 ± 1 84 ± 6 0 ± 11 45 ± 4 91 ± 2
11 95 ± 3 69 ± 2 75 ± 6 67 ± 17 63 ± 13 3 ± 10 5 ± 25 91 ± 2
Results of proteasome inhibition and viability measurements from experiment shown in Figure 5. Viability values are the same as in the graphs on
Figure 5. Values are averages ± SE of two (activity) or three (viability) independent measurements. Negative values indicate activation. Caspase-like
activity is presented in Table S2. See legend to Figure 5 for further experimental details.
a Cells were treated with bortezomib and carfilzomib for 1 hr, and activity was measured immediately after washout of the drug. NC-022 was added,
and 5 hr after NC-022 addition proteasome activity was measured again. Note that trypsin-like activity was inhibited by >90% but inhibition of the
chymotrypsin-like activity was not altered by NC-022 treatment. Viability was measured 48 hr after the start of the experiment.
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Inhibitors of Proteasome Trypsin-like Sitessites in the excision of specific epitopes is not known (Groettrup
and Schmidtke, 1999; Rock et al., 2002). Specific activity of the
trypsin-like sites of immunoproteasomes (b2i) is several-fold
higher than that of their counterparts in the constitutive particles
(b2) (Cascio et al., 2001). Some MHC class I ligands have basic
residues at the C terminus (Rammensee et al., 1995). The
C-termini of these specific peptides may be generated by cleav-
ages at the trypsin-like sites. Because of a lack of specific inhib-
itors of these sites, this hypothesis could not previously be
tested; it can be tested now using the reagents developed in
this work.
SIGNIFICANCE
The cell-permeable inhibitors of trypsin-like sites reported
here fill the largest remaining void in the impressive palette
of proteasome inhibitors available to biologists. This study
completes the development of site-specific inhibitors and
activity based probes of proteasome different active sites,
at least for the constitutive proteasome. These active sites
can now be downregulated individually to the desired extent
in living cells. Inhibitors developed in this study will findwide
use to study the role of trypsin-like sites in protein degrada-
tion, MHC class I antigen presentation and other biological616 Chemistry & Biology 18, 608–618, May 27, 2011 ª2011 Elsevierprocesses, and, as demonstrated in this study for multiple
myeloma, to determine whether these sites can be targeted
for the treatment of other cancers or different diseases.
EXPERIMENTAL PROCEDURES
Synthesis of Inhibitors
Synthesis of NC-002, NC-012, NC-022, and az-NC-002 and analytical data for
compounds are described in the Supplementary Materials section. Bortezo-
mib was purchased from LC laboratories. Carfilzomib was synthesized as
described (Britton et al., 2009; Demo et al., 2007; Zhou et al., 2009). BioP
was synthesized as described (Verdoes et al., 2008).
Proteasome Purification and Assays
26S proteasomes were purified from rabbit muscle as described (Screen et al.,
2010). To determine inhibition of purified proteasomes, they were incubated
with inhibitors for 30 min at 37C followed by assay of activity with fluorogenic
substrates Suc-LLVY-amc (chymotrypsin-like site), Ac-RLR-amc (trypsin-like
site), and Ac-nLPnLD-amc (caspase-like site). See Geurink et al. (2010) for
detailed description of the procedure. 12% Novex Bis-Tris gels (Invitrogen)
withMOPS running buffer were used for electrophoretic separation of catalytic
subunits modified by active-site probes. Inhibition of active sites inside cells
was assayed using luminescent ProteasomeGlo assay (Promega) (Moravec
et al., 2009) as described in our previous study (Britton et al., 2009). Results
of the cell-based ProteasomeGlo assay are undistinguishable from the activity
measurement with fluorogenic substrates in extracts, in which background
cleavage by non-proteasomal proteases is accounted for by subtractingLtd All rights reserved
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Inhibitors of Proteasome Trypsin-like Sitesactivity left in extract after treatment with high concentrations of highly specific
proteasome inhibitor epoxomicin (Britton et al., 2009) (see Figure S4B for data
and Supplemental Experimental Procedures for details of the assay with fluo-
rogenic substrates). Cathepsin B, H, L, S activity was measured with pan-
cathepsin substrate Z-FR-amc (Kirschke and Wiederanders, 1994) in extracts
of cytosol-less cells at pH 6.0 as described in the previous study (Screen et al.,
2010). Cathepsin D activity was measured in cytosol-less extracts using
SensoLyte520 Cathepsin D Fluorometric Assay Kit (AnaSpec). Combined
cathepsin D and E activity was measured using the same kit, in which
cathepsin D substrate provided with the kit was replaced with 7-Methoxycou-
marin-GKPILFFRLK(Dnp)-r-NH2 (where ‘‘r’’ stand for D-Arg) internally
quenched fluorogenic substrate of cathepsin D and E. In this case, we used
pH 3.0 assay buffer provided with the kit was used for cell extraction. All
activity observed using both procedures was inhibited by more than 98% by
specific inhibitor of aspartic proteases pepstatin A.
Cell Culture
All cells were cultured in RPMI-1640 supplemented with 10% fetal bovine
serum. Viability of multiple myeloma cells was measured with Alamar Blue
mitochondrial dye conversion assay. Viability of PBMNC was measured using
Cell Titer-Glo luminescent cell viability assay (Promega), which is based on
quantification of ATP present in the cells. Caspase-3/7 activity was measured
using ApoONE 3/7 homogeneous assay (Promega). (This assay uses
Ac-DEVD-Rhodamine110 cell permeable fluorogenic substrate.)
Isolation and Identification of Polypeptides Modified by az-NC-002
Cells were treated with the activity-based site probe overnight and lyzed with
50 mM Tris-HCl, 10% glycerol, 5 mM MgCl2, 0.5 mM EDTA, 0.5% CHAPS,
1 mM ATP. After 1 hr treatment with 100 mM BioP proteins were denatured
with 1% SDS, followed by affinity purification of biotinylated polypeptides on
Streptavidin coated magnetic beads. After on-beads trypsin digestion,
samples were analyzed by LC-MS/MS. See Florea et al. (2010) for the detailed
description of the procedure. IRDye 800 CW-conjugated Streptavidin was
purchased from Rockland, hsc71 antibodies from Abcam (Cat # 19136), and
b2 antibodies from Abgent (Cat #AP2914b).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, two tables and can be found with this article online at
doi:10.1016/j.chembiol.2011.02.015.
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